The effect of fish oil versus krill oil intervention on clinical symptoms and cardiometabolic risk factors in patients with major depressive disorder: A randomized placebo-controlled double-blind trial

dc.contributor.authorAcik, Murat
dc.contributor.authorCakiroglu, Funda Pinar
dc.contributor.authorTekin, Atilla
dc.contributor.authorEgeli, Asli
dc.date.accessioned2026-08-12T17:41:49Z
dc.date.issued2025
dc.departmentFırat Üniversitesi
dc.description.abstractBackground: This study aimed to compare the effects of krill- and fish-oil interventions on clinical symptoms and metabolic risk factors in individuals with MDD. Methods: In this randomized study, 57 adults diagnosed with MDD were allocated to receive krill-oil (520 mg EPA + DHA), fish-oil (600 mg EPA + DHA), or a placebo (soybean-oil) daily for 8 weeks. Anthropometric measurements, depression anxiety stress-21 (DASS-21) scale, and Hamilton depression rating scale (HDRS) were performed at baseline and 4 and 8 weeks. In addition, venous blood samples were collected at baseline and postintervention to evaluate lipid and glycemic profiles, including fasting glucose, HbA1c, cholesterol, triglycerides, LDL-c, and HDL-c levels.SPSS and R Studio software programs were used for statistical analysis. Results: A total of 50 participants completed the study, with 17 in each intervention group and 16 in the placebo. The mean HDRS scores decreased significantly in both the krill-oil (8.5 +/- 1.2) and fish-oil groups (10.0 +/- 1.2) compared to the placebo (p < 0.001), indicating clinical symptom improvement. Furthermore, the interaction effect of group-by-time was found to be statistically significant (eta 2p = 0.273;ptimexgroup < 0.001). Anxiety and distress scores decreased to similar levels after the post-intervention compared to baseline in krill- and fish-oil groups. Krill- and fish-oil supplementation increased plasma HDL-c and uric acid levels, but the group-by-time interaction effect was only observed at the HDL-c level (eta 2p = 0.238;ptimexgroup = 0.002). The mean HbA1c rates and plasma triglyceride levels of krill-oil recipients were lower after the post-intervention. Conclusion: Krill- and fish-oil could be considered as a safe and effective adjuvant treatments for depression. However, there was no evidence of apparent superiority over each other.
dc.identifier.doi10.1016/j.jad.2025.03.097
dc.identifier.endpage180
dc.identifier.issn0165-0327
dc.identifier.issn1573-2517
dc.identifier.orcid0000-0002-3104-6306
dc.identifier.orcid0000-0002-2281-6719
dc.identifier.orcid0000-0003-2324-6874
dc.identifier.pmid40118278
dc.identifier.scopus2-s2.0-105000708161
dc.identifier.scopusqualityQ1
dc.identifier.startpage171
dc.identifier.urihttps://doi.org/10.1016/j.jad.2025.03.097
dc.identifier.urihttps://hdl.handle.net/11508/59493
dc.identifier.volume380
dc.identifier.wosWOS:001457277300001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of Affective Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectDepression
dc.subjectN-3 PUFAs
dc.subjectAnxiety
dc.subjectDistress
dc.subjectMetabolic risk factors
dc.titleThe effect of fish oil versus krill oil intervention on clinical symptoms and cardiometabolic risk factors in patients with major depressive disorder: A randomized placebo-controlled double-blind trial
dc.typeArticle

Dosyalar